REACH: non-regulatory announcement*
AIM: FIPP
2
May 2024
Frontier IP Group
plc
("Frontier IP" or the
"Group")
Portfolio news - Frontier IP
announces stake in DiaGen
Frontier IP, a specialist in
commercialising intellectual property, today announces:
·
that the Group holds a 4.26 per cent stake in
DiaGen Ai Inc ("DiaGen"), a Canadian company focused on AI-driven
protein and peptide design for medical applications
·
and that DiaGen has entered into a Technology
Evaluation Agreement with the Group's portfolio company The Vaccine
Group ("TVG")
Frontier IP gained a stake in
DiaGen, formerly known as Proteic Bioscience Inc, in return for
advisory services. DiaGen was founded in 2021 to develop a
proprietary AI engine for protein design, drug discovery and
diagnostics for health, wellness, longevity, and precision
medicine.
This collaboration between DiaGen
and TVG will bring together complimentary approaches to developing
novel and better vaccines for use in animals. Initial focus will be
on broadly-protective vaccine candidates for a disease caused by a
virus which mutates frequently, making it harder to develop
effective vaccines.
Paolo Lobo, DiaGen President, said: "We are excited to further
iterate our proprietary AI capabilities into a new addressable
market in the Veterinary sector to optimize the ideal
protein structures for expression and immune stimulation to
complement TVG's experienced team in advancing their vaccine
pipeline."
TVG
Chief Executive Jeremy Salt said: "The
partnership with DiaGen will bring strong complementary AI
approaches to develop novel and improved vaccines. TVG's
herpesviral vector delivery system will be used to deliver optimal
antigens designed by DiaGen for expression in animal patients.
Initial focus will be on the development of broadly protective
vaccine candidates for a disease caused by a highly variable virus.
This new partnership with DiaGen represents a significant
development in TVG's ability to address key gaps in the veterinary
vaccine market."
Frontier IP Chief Executive Neil Crabb said:
"We have been working with DiaGen for some time.
The Technology Evaluation Agreement with TVG demonstrates the
benefits of our clusters approach, where expertise and know how can
be shared profitably between companies. I look forward to seeing
the successful results of this collaboration."
ENQUIRIES
|
Frontier IP Group Plc
|
T: 020 7332 2338
|
|
Neil Crabb, Chief
Executive
Andrew Johnson, Communications and
investor relations
andrew.johnson@frontierip.co.uk
Company
website: www.frontierip.co.uk
|
neil@frontierip.co.uk
M: 07464 546 025
|
|
Allenby Capital Limited (Nominated
Adviser)
|
T: 0203 328 5656
|
|
Nick Athanas / George
Payne
|
|
DiaGen Ai Inc
|
ir@diagen.ai
|
Brian Keane, CEO and
Chair
|
|
The
Vaccine Group
|
Jeremy.salt@thevaccinegroup.co.uk
|
Jeremy Salt, CEO
|
|
|
| |
ABOUT FRONTIER IP
Frontier IP unites science,
finance and industry by identifying strong intellectual property
and accelerating its development through a range of
commercialisation services. A critical part of the Group's work is
involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a
portfolio of equity stakes and licence income by taking an active
involvement in spin-out companies, including support for fund
raising and collaboration with relevant industry partners at an
early stage of development.
*
About Reach announcements
This is a RNS Reach announcement.
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be
disseminated as an RNS regulatory announcement and not on
Reach.